Medical Watch Disease & Treatment News

FDA Approves Nelkarmi for Previously Treated ALK-Positive Lung Cancer

FDA Approves Nelkarmi for Previously Treated ALK-Positive Lung Cancer

Nelkarmi offers a new targeted option for previously treated ALK-positive lung cancer. Single-arm studies reported response rates of 49% after alectinib and 32% after multiple ALK inhibitors plus chemotherapy; accelerated approval means confirmatory evidence is still needed, with liver, kidney, eye, and muscle-related risks relevant.

Sources (2)
Updated Nov 18, 2026